Bioresorbable Vascular Scaffolds

Global Bioresorbable Vascular Scaffolds Market to Reach US$640.0 Million by 2030

The global market for Bioresorbable Vascular Scaffolds estimated at US$422.5 Million in the year 2024, is expected to reach US$640.0 Million by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Peripheral Artery Application, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$376.9 Million by the end of the analysis period. Growth in the Coronary Artery Application segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$115.1 Million While China is Forecast to Grow at 11.5% CAGR

The Bioresorbable Vascular Scaffolds market in the U.S. is estimated at US$115.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$136.2 Million by the year 2030 trailing a CAGR of 11.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Bioresorbable Vascular Scaffolds Market – Key Trends & Drivers Summarized

Why Are Bioresorbable Vascular Scaffolds Gaining Momentum in Cardiovascular Treatments?

Bioresorbable vascular scaffolds (BVS) are revolutionizing the treatment of coronary artery disease (CAD) by offering a temporary structural solution that naturally dissolves over time, leaving behind a healed vessel. Unlike traditional metallic stents, which remain permanently in the artery, bioresorbable scaffolds are designed to provide mechanical support during the critical healing phase and then gradually degrade, restoring natural vessel function. This next-generation technology addresses long-term complications associated with permanent stents, such as late-stent thrombosis, vessel caging, and inflammation.

The growing global prevalence of cardiovascular diseases, coupled with the increasing demand for minimally invasive procedures, has propelled the adoption of bioresorbable vascular scaffolds. Patients and cardiologists are increasingly favoring these devices due to their potential to improve long-term outcomes and reduce the need for repeat interventions. Additionally, advancements in polymer science and bioresorbable metal alloys are enhancing scaffold strength, degradation control, and biocompatibility, making BVS a promising alternative to traditional stents. As healthcare systems prioritize patient-centric and cost-effective solutions, BVS is emerging as a key innovation in interventional cardiology.

How Are Technological Advancements Improving Bioresorbable Vascular Scaffolds?

Innovations in biomaterials, scaffold design, and drug-eluting technology are driving the evolution of bioresorbable vascular scaffolds, improving their safety, efficacy, and clinical performance. One of the most significant advancements in this field is the development of high-strength bioresorbable polymers, such as poly-L-lactic acid (PLLA), which provide sufficient radial support while ensuring controlled degradation over time. Additionally, researchers are exploring magnesium-based bioresorbable scaffolds that offer improved mechanical strength and faster resorption, reducing concerns related to prolonged polymer presence in the arteries.

Another major breakthrough is the incorporation of drug-eluting coatings that help prevent restenosis by releasing antiproliferative agents such as sirolimus or everolimus during the initial healing phase. These drug-eluting bioresorbable scaffolds have demonstrated promising clinical outcomes by reducing in-stent restenosis rates while ensuring optimal vascular healing. Furthermore, computational modeling and AI-driven optimization techniques are enhancing scaffold design, leading to thinner strut profiles and improved flexibility, which reduce complications such as scaffold thrombosis. As these technological advancements continue to refine BVS performance, the adoption of these next-generation devices is expected to accelerate in interventional cardiology.

Which Market Trends Are Driving Growth in the Bioresorbable Vascular Scaffolds Industry?

The increasing prevalence of coronary artery disease and the rising number of percutaneous coronary interventions (PCIs) are among the most significant trends fueling the growth of the bioresorbable vascular scaffold market. With cardiovascular diseases remaining the leading cause of mortality worldwide, healthcare providers are prioritizing innovative solutions that improve long-term patient outcomes. The demand for BVS is also being driven by a shift toward minimally invasive and patient-friendly interventions, where bioresorbable technology aligns with the broader goal of reducing long-term foreign material presence in the body.

Another key trend shaping the market is the increasing regulatory support for bioresorbable scaffolds. While earlier-generation BVS faced concerns over scaffold thrombosis and suboptimal degradation rates, recent innovations in material science and clinical data have led to renewed interest from regulatory agencies and healthcare professionals. Additionally, the expansion of bioresorbable technology beyond coronary interventions—into peripheral artery disease (PAD) and other vascular conditions—is opening new market opportunities. As clinical trials continue to validate the benefits of BVS, and more next-generation devices receive regulatory approvals, the market is poised for significant expansion in both developed and emerging economies.

What Are the Key Growth Drivers Shaping the Future of the Bioresorbable Vascular Scaffolds Market?

The growth in the bioresorbable vascular scaffold market is driven by multiple factors, including technological advancements, increasing clinical adoption, and a growing emphasis on long-term patient outcomes. One of the primary growth drivers is the rising burden of cardiovascular diseases, which necessitates innovative and effective treatment options. As patient populations expand, particularly in aging demographics and high-risk groups, the demand for bioresorbable scaffolds is expected to increase.

Another crucial driver shaping the market is the strong investment in research and development (R&D) by medical device companies and academic institutions. Continuous improvements in scaffold design, resorption kinetics, and drug-eluting capabilities are enhancing the clinical feasibility of BVS technology. Additionally, strategic collaborations between healthcare providers, medical institutions, and biotech firms are accelerating the commercialization of advanced bioresorbable scaffolds. The increasing adoption of value-based healthcare models, which prioritize long-term patient benefits over short-term procedural costs, is also expected to boost the demand for BVS. As these factors continue to drive innovation and adoption, bioresorbable vascular scaffolds are set to redefine the future of coronary and peripheral artery disease management, improving patient outcomes while reducing long-term healthcare costs.

SCOPE OF STUDY:

The report analyzes the Bioresorbable Vascular Scaffolds market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Application (Peripheral Artery Application, Coronary Artery Application); End-Use (Hospitals End-Use, Ambulatory Care Centers (ACS) End-Use, Specialty Clinics End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Cardiovascular
• BD
• Biotronik AG
• Boston Scientific Corporation
• Elixir Medical Corporation
• Kyoto Medical Planning Co., Ltd
• Meril Life Sciences
• MicroPort
• Reva Medical Inc
• Shandong Huaan Biotechnology Co.,Ltd
• Terumo Interventional Systems
• W. L. Gore & Associates, Inc.
• Zeus Inc

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.